Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Second Line Treatment of Gastric Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT01070290
What this trial is testing

ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen

Who this might be right for
Gastric Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Post-approval studies (Phase 4)UnknownNCT05029453
What this trial is testing

Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy

Who this might be right for
Gastric CancerRandomized Controlled Study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 60
Large-scale testing (Phase 3)Study completedNCT00821990
What this trial is testing

Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer

Who this might be right for
Advanced Gastric Cancer
Samsung Medical Center 200
Testing effectiveness (Phase 2)Looking for participantsNCT07392346
What this trial is testing

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Who this might be right for
Gastric Cancer Adenocarcinoma Metastatic
Dai, Guanghai 68
Testing effectiveness (Phase 2)Ended earlyNCT01402401
What this trial is testing

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

Who this might be right for
Advanced Gastric Cancer
Novartis Pharmaceuticals 21
Testing effectiveness (Phase 2)Looking for participantsNCT05640830
What this trial is testing

Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

Who this might be right for
HER2-positive Advanced Gastric Cancer
Kangbuk Samsung Hospital 47
Testing effectiveness (Phase 2)Study completedNCT01576380
What this trial is testing

A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients

Who this might be right for
Adenocarcinoma, ScirrhousLinitis PlasticaStomach Neoplasms+3 more
Novartis Pharmaceuticals 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT06992024
What this trial is testing

Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer

Who this might be right for
Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06697366
What this trial is testing

Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer

Who this might be right for
Gastric Cancer
Ruijin Hospital 27
Not applicableUnknownNCT03531931
What this trial is testing

Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial

Who this might be right for
Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety
The First Affiliated Hospital of Xiamen University 20
Testing effectiveness (Phase 2)Study completedNCT01482299
What this trial is testing

RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression

Who this might be right for
Stomach Neoplasm
Asan Medical Center 45
Testing effectiveness (Phase 2)UnknownNCT04656002
What this trial is testing

As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

Who this might be right for
Gastric Cancer
Samsung Medical Center 43
Testing effectiveness (Phase 2)UnknownNCT03966118
What this trial is testing

Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma

Who this might be right for
Gastroesophageal Junction AdenocarcinomaAdenocarcinoma of the Stomach
P. C. Thuss-Patience 59
Testing effectiveness (Phase 2)WithdrawnNCT05512182
What this trial is testing

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Who this might be right for
Recurrent/Advanced Gastric Cancer
Yonsei University
Testing effectiveness (Phase 2)Study completedNCT04835896
What this trial is testing

Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer

Who this might be right for
Recurrent/Metastatic Gastric Cancer
Yonsei University 49
Testing effectiveness (Phase 2)Study completedNCT02999295
What this trial is testing

Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Region (GEJ) Cancer
National Cancer Center, Japan 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07689292
What this trial is testing

Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaGastro-esophageal Junction Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06904300
What this trial is testing

Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

Who this might be right for
Gastric (Cardia, Body) Cancer
Sun Yat-sen University 110
Not applicableNot Yet RecruitingNCT06814548
What this trial is testing

Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study

Who this might be right for
Gastric Cancer, Gastroesophageal Junction CancerImmune Checkpoint Inhibitors (ICIs)Second-line+1 more
Yongxu Jia 200
Not applicableUnknownNCT04443036
What this trial is testing

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Who this might be right for
Gastric Carcinoma
China Medical University, China 44
Next Page